Literature DB >> 15328423

Smoking history and serum cotinine and thiocyanate concentrations as determinants of rheumatoid factor in non-rheumatoid subjects.

T Korpilähde1, M Heliövaara, P Knekt, J Marniemi, A Aromaa, K Aho.   

Abstract

OBJECTIVES: Smoking is associated with false-positive rheumatoid factor (RF). We explored the dose-response relationship of this association, using smoking history and serum cotinine and thiocyanate concentrations as measures of tobacco exposure.
METHODS: A total of 6947 men and women aged 30 yr or over and free of clinical arthritis were included in the Mini-Finland Health Survey carried out between 1978 and 1980. Detailed histories of smoking and RF (sensitized sheep cell agglutination test) were obtained in the basic examination. In 2000, serum cotinine and thiocyanate were determined from serum samples collected at baseline and stored at -20 degrees C. A cut-off point of 100 microg/l was used for serum cotinine and 10 micromol/l for thiocyanate to indicate active smoking.
RESULTS: There was a close association between smoking and strongly positive RF. After adjustment for age, sex, coffee consumption and region, the odds ratios (95% confidence intervals in brackets) in current smokers and in those who had quit smoking were 3.94 (2.04-7.61) and 2.71 (1.33-5.53), respectively, compared with those who had never smoked. Among current smokers, the intensity, duration or tertiles of pack-years of smoking were not related to RF. No relationship between serum cotinine or thiocyanate and RF positivity was observed within the subgroups of current smokers and those who had quit. Among those who reported that they had never smoked but who nevertheless had serum cotinine levels at least 100 microg/l, the adjusted odds ratio of strongly positive RF was 4.48 (1.48-13.50) compared with people who had never smoked and whose serum cotinine levels were less than 100 microg/l.
CONCLUSIONS: The results are not in line with the hypothesis of a dose-response relationship between smoking exposure and RF positivity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15328423     DOI: 10.1093/rheumatology/keh365

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  11 in total

1.  Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles.

Authors:  S P Linn-Rasker; A H M van der Helm-van Mil; F A van Gaalen; M Kloppenburg; R R P de Vries; S le Cessie; F C Breedveld; R E M Toes; T W J Huizinga
Journal:  Ann Rheum Dis       Date:  2005-07-13       Impact factor: 19.103

2.  Increased inflammation and disease activity among current cigarette smokers with rheumatoid arthritis: a cross-sectional analysis of US veterans.

Authors:  Jeremy Sokolove; Catriona A Wagner; Lauren J Lahey; Harlan Sayles; Michael J Duryee; Andreas M Reimold; Gail Kerr; William H Robinson; Grant W Cannon; Geoffrey M Thiele; Ted R Mikuls
Journal:  Rheumatology (Oxford)       Date:  2016-07-31       Impact factor: 7.580

Review 3.  Can rheumatoid arthritis be prevented?

Authors:  Kevin D Deane
Journal:  Best Pract Res Clin Rheumatol       Date:  2013-10-02       Impact factor: 4.098

4.  The activity of the immunoregulatory enzyme indoleamine 2,3-dioxygenase is decreased in smokers.

Authors:  M Pertovaara; M Heliövaara; A Raitala; S S Oja; P Knekt; M Hurme
Journal:  Clin Exp Immunol       Date:  2006-09       Impact factor: 4.330

Review 5.  Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation.

Authors:  Kevin D Deane; Jill M Norris; V Michael Holers
Journal:  Rheum Dis Clin North Am       Date:  2010-05       Impact factor: 2.670

6.  The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases.

Authors:  Ct Chou; Ht Liao; Ch Chen; Ws Chen; Hp Wang; Ky Su
Journal:  Biomark Insights       Date:  2007-05-03

7.  Circulating anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis and chronic obstructive pulmonary disease.

Authors:  Deng-Ho Yang; Chuan-Chou Tu; Shou-Cheng Wang; Cheng-Chung Wei; Ya-Wen Cheng
Journal:  Rheumatol Int       Date:  2013-12-24       Impact factor: 2.631

8.  Autoantibodies in silicosis patients and in silica-exposed individuals.

Authors:  Gabriel Zaghi; Fábio Koga; Renato M Nisihara; Thelma L Skare; Antonieta Handar; Shirley R Rosa Utiyama; Marilia Barreto Silva
Journal:  Rheumatol Int       Date:  2009-08-25       Impact factor: 2.631

9.  Deterioration of lung function is associated with presence of IgM rheumatoid factor and smoking in patients with systemic sclerosis.

Authors:  Berit Broholm; Susanne Ullman; Poul Halberg; Søren Jacobsen
Journal:  Clin Rheumatol       Date:  2008-06-05       Impact factor: 2.980

Review 10.  Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE.

Authors:  Kevin D Deane; Hani El-Gabalawy
Journal:  Nat Rev Rheumatol       Date:  2014-02-11       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.